Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Locked Dimerized CXCL12 Exerts Radiosensitizing Effects in Head and Neck Cancer. Head Neck 2025 May;47(5):1379-1391

Date

12/26/2024

Pubmed ID

39722591

Pubmed Central ID

PMC12040585

DOI

10.1002/hed.28048

Scopus ID

2-s2.0-85212965471 (requires institutional sign-in at Scopus site)

Abstract

BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) presents significant treatment challenges, particularly in cases unrelated to human papillomavirus (HPV). The chemokine receptor CXCR4, interacting with its ligand CXCL12, plays a crucial role in tumor proliferation, metastasis, and treatment resistance. This study explores the therapeutic potential of engineered monomeric and dimerized CXCL12 variants (CXCL121 and CXCL122, respectively) in HNSCC and evaluates potential additive effects when combined with radiation therapy.

METHODS: Clinical HNSCC biopsies were evaluated for CXCR4 expression in both previously untreated and radiorecurrent disease. HNSCC cell lines were then treated with combinations of CXCL12 variants and radiotherapy and interrogated for proliferation, gene expression change, and underlying molecular mechanisms. In vivo studies evaluated the biodistribution of engineered CXCL12 and tested these treatments in humanized cell line-derived xenograft (CDX) models.

RESULTS: CXCL122 significantly reduced HNSCC cell proliferation and enhanced the effects of radiotherapy, likely through biased agonism at the CXCR4 receptor and upregulation of the KISS1R pathway. In vivo, CXCL122 localized to tumor sites and augmented the effects of radiation to inhibit tumor growth.

CONCLUSIONS: CXCL122, in combination with radiation, demonstrates potent anti-tumor effects in HNSCC. These findings support further clinical investigation of CXCL122 to enhance the effects of radiotherapy.

Author List

Espinosa OV, Awan M, Memon AA, Frei A, Foeckler J, Kuehn R, Bruening J, Massey B, Wong S, Shukla M, Kasprzak J, Joshi A, Dwinell MB, Himburg HA, Zenga J

Authors

Musaddiq J. Awan MD Associate Professor in the Radiation Oncology department at Medical College of Wisconsin
Jennifer D. Bruening MD Assistant Professor in the Otolaryngology department at Medical College of Wisconsin
Heather A. Himburg PhD Professor in the Radiation Oncology department at Medical College of Wisconsin
Amit Joshi PhD Professor in the Biomedical Engineering department at Medical College of Wisconsin
Becky Massey MD Associate Professor in the Otolaryngology department at Medical College of Wisconsin
Monica E. Shukla MD Associate Professor in the Radiation Oncology department at Medical College of Wisconsin
Joseph Zenga MD Chief, Associate Professor in the Otolaryngology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Animals
Carcinoma, Squamous Cell
Cell Line, Tumor
Cell Proliferation
Chemokine CXCL12
Female
Head and Neck Neoplasms
Humans
Male
Mice
Radiation-Sensitizing Agents
Receptors, CXCR4
Xenograft Model Antitumor Assays